A Study of Pyrotinib Combined With Capecitabine for Metastatic HER-2 Positive Colorectal Cancer
Status:
Not yet recruiting
Trial end date:
2023-01-10
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy and safety of pyrotinib combined with capecitabine in patients with
metastatic her-2 positive colorectal cancer after standard treatment.